ClinicalTrials.gg
RecruitingNCT06917079Updated Jun 2, 2026

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A Phase 1 interventional study of BBO-11818 and Pembrolizumab in Non-Small Cell Lung Cancer, NSCLC and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (formerly part of BridgeBio) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
665
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
173rd of 2,998
665 · median 56
Started
2025
with 148 others
Phase 1
927 of 3,371
134 open now
Primary completion
2027-08
later than 445 of 892 live
Registered
3,164th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 173rd largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 149 that started in 2025, is one of 927 in phase 1, reaches primary completion later than 445 of the 892 other live ones, and was the 3,164th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Read the detailed description

This is an open-label, multi-center, Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BBO-11818, a pan-KRAS inhibitor, alone and in combination with pembrolizumab, pembrolizumab + cis/carboplatin + pemetrexed, cetuximab, cetuximab + mFOLFOX6, BBO-10203 + mFOLFOX6, BBO-10203 +cetuximab, mFOLFIRINOX, gemcitabine + nab-paclitaxel, or BBO-10203 in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. The study includes a dose escalation phase and a dose expansion phase.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • NSCLC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • CRC (Colorectal Cancer)
  • Metastatic Non-Small Lung Cell Cancer
  • Metastatic Colorectal Cancer (CRC)
  • KRAS G12A
  • KRAS G12C
  • KRAS G12D
  • KRAS G12S
  • KRAS G12V
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Advanced Lung Carcinoma
  • Solid Tumor, Adult

Keywords

  • BBOT
  • BridgeBio Oncology Therapeutics
  • Phase1
  • Phase 1a/1b
  • NSCLC
  • CRC
  • PDAC
  • Metastatic Cancer
  • Advanced Cancer
  • Pembrolizumab
  • Cetuximab
  • Platinum Chemotherapy
  • Pemetrexed
  • KONQUER
  • KONQUER-101
  • mFOLFOX6
  • mFOLFIRINOX
  • Gemcitabine
  • Nab-paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented locally advanced and unresectable or NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
  • by v1.1
  • (ECOG) performance status (PS) 0-1
  • >24 weeks
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • within the last 2 years as specified in the protocol
  • Untreated

Other inclusion/exclusion criteria are specified in the protocol.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
665 participants (estimated)

Study arms

  • Experimental
    Cohort 1a - Dose Escalation Monotherapy

    Participants enrolled in this cohort will receive BBO-11818 as monotherapy

    Drug: BBO-11818

  • Experimental
    Cohort 1b - Dose Escalation Combination Therapy (Pembrolizumab)

    Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV)

    Drug: BBO-11818 · Drug: Pembrolizumab

  • Experimental
    Cohort 1c - Dose Escalation Combination Therapy (Pembrolizumab + Cis/carboplatin + Pemetrexed)

    Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV), cis/carboplatin infusion (IV), and pemetrexed infusion (IV)

    Drug: BBO-11818 · Drug: Pembrolizumab · Drug: Platinum chemotherapy (cisplatin or carboplatin) · Drug: Pemetrexed

  • Experimental
    Cohort 1d - Dose Escalation Combination Therapy (Cetuximab ± mFOLFOX6)

    Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV) with or without mFOLFOX6 infusion (IV)

    Drug: BBO-11818 · Drug: Cetuximab · Drug: mFOLFOX6

  • Experimental
    Cohort 1e - Dose Escalation Combination Therapy (BBO-10203 + mFOLFOX6)

    Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and mFOLFOX6 infusion (IV)

    Drug: BBO-11818 · Drug: mFOLFOX6 · Drug: BBO-10203

  • Experimental
    Cohort 1f - Dose Escalation Combination Therapy (BBO-10203 + Cetuximab)

    Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and cetuximab infusion (IV)

    Drug: BBO-11818 · Drug: Cetuximab · Drug: BBO-10203

  • Experimental
    Cohort 1g - Dose Escalation Combination Therapy (Cetuximab)

    Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV)

    Drug: BBO-11818 · Drug: Cetuximab

  • Experimental
    Cohort 1h - Dose Escalation Combination Therapy (mFOLFIRINOX)

    Participants enrolled in this cohort will receive BBO-11818 in combination with mFOLFIRINOX infusion (IV)

    Drug: BBO-11818 · Drug: mFOLFIRINOX

  • Experimental
    Cohort 1i - Dose Escalation Combination Therapy (Gemcitabine + Nab-paclitaxel)

    Participants enrolled in this cohort will receive BBO-11818 in combination with gemcitabine infusion (IV) and nab-paclitaxel infusion (IV)

    Drug: BBO-11818 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Cohort 1j - Dose Escalation Combination Therapy (BBO-10203)

    Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203

    Drug: BBO-11818 · Drug: BBO-10203

  • Experimental
    Cohort 2a - Dose Expansion Monotherapy

    Participants enrolled in this cohort will receive BBO-11818 as monotherapy

    Drug: BBO-11818

  • Experimental
    Cohort 2b - Dose Expansion Combination (Pembrolizumab)

    Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV)

    Drug: BBO-11818 · Drug: Pembrolizumab

  • Experimental
    Cohort 2c - Dose Expansion Combination Therapy (Pembrolizumab + Cis/carboplatin + Pemetrexed)

    Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV), cis/carboplatin infusion (IV), and pemetrexed infusion (IV)

    Drug: BBO-11818 · Drug: Pembrolizumab · Drug: Platinum chemotherapy (cisplatin or carboplatin) · Drug: Pemetrexed

  • Experimental
    Cohort 2d - Dose Expansion Combination Therapy (Cetuximab ± mFOLFOX6)

    Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV) with or without mFOLFOX6 infusion (IV)

    Drug: BBO-11818 · Drug: Cetuximab · Drug: mFOLFOX6

  • Experimental
    Cohort 2e - Dose Expansion Combination Therapy (BBO-10203 + mFOLFOX6)

    Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and mFOLFOX6 infusion (IV)

    Drug: BBO-11818 · Drug: mFOLFOX6 · Drug: BBO-10203

  • Experimental
    Cohort 2f - Dose Expansion Combination Therapy (BBO-10203 + Cetuximab)

    Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and cetuximab infusion (IV)

    Drug: BBO-11818 · Drug: Cetuximab · Drug: BBO-10203

  • Experimental
    Cohort 2g - Dose Expansion Combination Therapy (Cetuximab)

    Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV)

    Drug: BBO-11818 · Drug: Cetuximab

  • Experimental
    Cohort 2h - Dose Expansion Combination Therapy (mFOLFIRINOX)

    Participants enrolled in this cohort will receive BBO-11818 in combination with mFOLFIRINOX infusion (IV)

    Drug: BBO-11818 · Drug: mFOLFIRINOX

  • Experimental
    Cohort 2i - Dose Expansion Combination Therapy (Gemcitabine + Nab-paclitaxel)

    Participants enrolled in this cohort will receive BBO-11818 in combination with gemcitabine infusion (IV) and nab-paclitaxel infusion (IV)

    Drug: BBO-11818 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Cohort 2j - Dose Expansion Combination Therapy (BBO-10203)

    Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203

    Drug: BBO-11818 · Drug: BBO-10203

Interventions

  • DrugBBO-11818

    Participants will receive assigned dose of BBO-11818 orally (PO)

  • Patients will receive IV pembrolizumab

  • DrugPlatinum chemotherapy (cisplatin or carboplatin)

    Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)

  • Patients will receive IV pemetrexed

  • Patients will receive IV cetuximab

  • DrugmFOLFOX6

    Patients may receive IV mFOLFOX6

  • DrugmFOLFOX6

    Patients will receive IV mFOLFOX6

  • DrugBBO-10203

    Participants will receive BBO-10203 orally (PO)

  • DrugmFOLFIRINOX

    Patients will receive IV mFOLFIRINOX

  • Patients will receive IV gemcitabine

  • Patients will receive IV nab-paclitaxel

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

    Time frame: approximately 5 years

  2. Determine recommended dose of BBO-11818 in combination with pembrolizumab ± cis/carboplatin + pemetrexed, cetuximab ± mFOLFOX6, BBO-10203 + mFOLFOX6, BBO-10203 + cetuximab, cetuximab, mFOLFIRINOX, gemcitabine + nab-paclitaxel, or BBO-10203

    Time frame: approximately 5 years

Secondary outcomes

  1. Objective response rate (ORR) per RECIST v1.1 and CNS RECIST

    Time frame: approximately 5 years

  2. Clinical benefit rate (CBR) per RECIST v1.1

    Time frame: approximately 5 years

  3. Duration of Response (DOR) per RECIST v1.1

    Time frame: approximately 5 years

  4. Progression-Free Survival (PFS) per RECIST v1.1

    Time frame: approximately 5 years

  5. Overall Survival (OS)

    Time frame: approximately 5 years

  6. Pharmacokinetics of BBO-11818, BBO-10203, irinotecan, and its metabolites (SN-38 and SN-38-G): Maximum blood concentration (Cmax)

    Time frame: approximately 5 years

  7. Pharmacokinetics of BBO-11818, BBO-10203, irinotecan, and its metabolites (SN-38 and SN-38-G): Time to achieve maximum concentration (Tmax)

    Time frame: approximately 5 years

  8. Pharmacokinetics of BBO-11818, BBO-10203, irinotecan, and its metabolites (SN-38 and SN-38-G): Area under the concentration-time curve (AUC)

    Time frame: approximately 5 years

07

Study locations

17 of 17 sites recruiting
08

References and documents

Publications

  • Stahlhut C, Maciag AE, Sullivan KA, Singh K, Gitego N, Zhang Z, Chan AH, Sharma AK, Alexander PA, Shu J, Yang Y, Rigby M, Ma R, Setoodeh S, Smith BP, Pei J, Rabara D, Larsen EK, Turner DM, Zhang C, Feng C, Feng S, Stice JP, Xu R, Lin K, Stephen AG, Lightstone FC, Ji C, Wang K, Simanshu DK, Nissley DV, Wallace E, Wang B, Sinkevicius KW, McCormick F, Beltran PJ. Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants. Cancer Discov. 2026 Apr 1;16(4):740-759. doi: 10.1158/2159-8290.CD-25-1280. PubMed 41790032 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2027, 29 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2029
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06917079
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Mar 31, 2025
Primary completion
Aug 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jun 2, 2026

Study contacts

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Contact
tbbo11818-101ct.gov@bbotx.com
(650) 405-4770

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion